Glutamic acid decarboxylase antibodies (GAD), ZNT8 and IA2 testing are performed as a profile for diabetes
CSF GAD antibodies for neurological disorders- is on a different code- review Pathtest.
GENERAL NOTES
INTERPRETATION: GAD antibodies are present in >70% of diabetic patients treated with insulin but only 10% of those maintained on oral hypoglycaemic agents.
GAD antibodies may also be paired with CSF GAD antibodies for the investigation of CNS disorders.